Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in SLE
NCT02932137Completed
- Sponsor
- Peking University People's Hospital
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of aldesleukin in systemic lupus erythematosus (SLE) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Immunological Responses at 10 weeks. Started May 2016; status: completed.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02932137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932137.